title: Pharmacokinetic and pharmacodynamic end points with anti-VEGFR: the more it hurts, the more it works?
authors.affiliation: Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France olivier.mir@gustaveroussy.fr.
authors.forename: O
authors.initials: O
authors.lastname: Mir
authors.affiliation: Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France.
authors.forename: S
authors.initials: S
authors.lastname: Dumont
authors.affiliation: Department of Drug Development, Gustave Roussy Cancer Campus, Villejuif, France.
authors.forename: J-P
authors.initials: JP
authors.lastname: Armand
mesh_terms: D001794:Blood Pressure / Q000187:drug effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007191:Indazoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
chemical_list: D007093:Imidazoles; D007191:Indazoles; D047428:Protein Kinase Inhibitors